3Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs) : a review. Eur J Cancer,2002, 38 : S39 -S51.
5Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299:708 -710.
6Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency,, spectrum and in vitro sensitivity to imatinib. J Clin Oncol, 2005, 23:5357-5364.
7Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase Ⅰ and Ⅱ studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004,40:689-695.
8Noma K, Naomoto Y, Gunduz M, et al. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.Oncol Rep, 2005, 14:645-650.
9Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol,2002, 33:459-465.
10Lasota J, Jasinski M, Satlomo-Rikala M, et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol, 1999, 154:53-60.
1Mawr MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis[J]. Am J Surg Pathol,1983,7(6):507-519.
2ESMO/European Sarcoma Network Working Group. Gas- trointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2014,25(Suppl 3):iii21-iii26.
3Demetri GD, Baker LH, Beech D, et al. Soft tissue sarcoma clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2005,3(2): 158-194.
4Hsiao CY, Yang CY, Lai IR, et al. Laparoscopic resec- tion for large gastrointestinal stromal tumors (GIST): inter- mediate follow-up results [J]. Surg Endosc,2015,29 (4): 868-873.
